Amgen’s Aimovig (erenumab-aooe) Receives FDA’s Approval for Prevention of Migraine in Adults

 Amgen’s Aimovig (erenumab-aooe) Receives FDA’s Approval for Prevention of Migraine in Adults

Amgen Reports In-Favor Uphold of its Two Patents for Repatha from Delaware Jury

Shots:

  • The approval is based on P-IIIb LIBERTY (NCT03096834) study results assessing Aimovig (140mg) vs PBO for duration of 12 weeks
  • The study resulted in 50% reduction of monthly migraine days sustained up to 15 months with the use of acute migraine drugs
  • Aimovig (erenumab-aooe) is a novel drug used for targeting Calcitonin Gene-Related Peptide Receptor (CGRP-R), with its awaited EMA approval

Click here to read full press release/ article | Ref: Amgen | Image: Axios

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post